(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas was host to the Bladder Cancer Course and the session Metastatic Urothelial Cancer. Dr. Vadim S. Koshkin ...

Discover a study comparing two types of treatment for bladder cancer, robot-assisted radical cystectomy and intracorporeal ...

Discover the trials that have shown why Predictive biomarkers are expected to play a pivotal role in further enhancing ...

The following is a summary of “Immune checkpoint inhibitor therapy as a neoadjuvant treatment for muscle-invasive bladder ...

The FDA has approved a new drug, zanidatamab, for adults with advanced biliary tract cancer, or BTC. Marketed under the brand ...

Treatment with UGN-102 in patients with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer demonstrated ...

Every so often there is an urgent call for a national prostate cancer screening program to be introduced, usually following ...

Recent advances in immunotherapy and combination therapies are revolutionizing the treatment landscape for both metastatic ...

At ESMO 2024, Dr. Andrea Necchi presented the results of an interim analysis of SunRISe-4, noting a pathological complete response rate in the combination arm of 42% and pathologic objective response ...

Breast, bladder, and pancreatic cancers are increasingly being treated with a broad range of therapies before a patient ...

Initial Keytruda showed consistent antitumor activity and safety in patients with advanced bladder cancer ineligible for ...

Key TakeawaysFirst-ever annual report from the American College of Surgeons National Cancer Database includes in-depth data ...